Axsome Therapeutics AXSM Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's pre-tax income?
- Axsome Therapeutics (AXSM) reported pre-tax income of -$64.54M in Q1 2026.
- How has Axsome Therapeutics's pre-tax income changed year-over-year?
- Axsome Therapeutics's pre-tax income decreased by 8.6% year-over-year, from -$59.41M to -$64.54M.
- What is the long-term trend for Axsome Therapeutics's pre-tax income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's pre-tax income has grown at a 8.9% compound annual growth rate (CAGR), from -$130.4M to -$183.7M.
- What does pre-tax income mean?
- The company's profit before paying income taxes.
- How do you interpret pre-tax income?
- An increase indicates higher operational profitability or improved non-operating income, while a decrease suggests lower margins or increased non-operating costs.
- How does pre-tax income compare across companies?
- Standard across all public companies; peers in the biopharma sector often show negative values during intensive R&D phases.